Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus

Trial Profile

Study to evaluate the safety and efficacy of PAZ320 when added to oral agents or insulin in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs BTI 320 (Primary) ; Antihyperglycaemics; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Boston Therapeutics
  • Most Recent Events

    • 22 Sep 2014 Results published in a Boston Therapeutics media release.
    • 04 Sep 2013 Results have been published in the July/August issue of Endocrine Practice according to a Boston Therapeutics media release. Results were also summarised in the media release.
    • 26 Feb 2013 Results have been published electronically in an abstract ahead of print in Endocrine Practice according to a Boston Therapeutics media release. The full article is expected to be published in the July/August issue of the journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top